Arrhythmias & electrophysiology
Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry
Authors' conclusion
Anticoagulated patients with HF at baseline featured higher rates of major bleeding and all-cause death
Study context
- Population
- Edoxaban-treated patients with atrial fibrillation (AF), ETNA-AF-Europe registryLeft ventricular ejection fraction (LVEF) available in 82.4% of heart failure (HF)
- Participants
- 13,133 patients
- Exposure
- AF patients on edoxaban with vs without HF
- HFn = 1,854
- Outcome
- Ischaemic stroke/TIA/SEE, major bleeding and mortality
- Follow-up
- 2-year follow-up
Methodological detailsmulticentre, 4-year follow-up (2-year reported)
- Multicentre
- 4-year follow-up (2-year reported)
Main finding
As reported in the abstract
2 years
HF
- Any stroke/systemic embolic events (SEE)
- 0.86%/year
- All-cause death
- 8.30%/year
No HF
- Any stroke/SEE
- 0.67%/year
- All-cause death
- 3.17%/year
Any stroke/systemic embolic events (SEE)
HF0.86%/year
No HF0.67%/year
All-cause death
HF8.30%/year
No HF3.17%/year
Each group vs no HFHazard ratio (95% CI)
HF LVEF <40%
2.42(1.95–3.00)
HF LVEF ≥40%
1.80(1.45–2.23)
Observational data: associations, not effects.
Safety
| Outcome | HF | No HF | HR (95% CI) | |
|---|---|---|---|---|
| Major bleeding · 2 yearsMultivariate Cox · annualized event rates | 1.73%/year | 0.86%/year | 1.65 (1.20–2.26) | |
| 0.512Hazard ratio (log scale) |
Original publication
Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry. Europace. Published 15 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →